Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: A 2-year placebo-controlled trial

Osteoporosis International

Volumn 13, Issue 2, 2002, Pages 176-183

  Arrenbrecht, S ^a   Boermans, A J M ^b  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

^b NONE   (Netherlands)

Author keywords

Bone density; Bone turn over markers; Clinical; Estradiol replacement therapy; Postmenopause; Transdermal

Indexed keywords

ALKALINE PHOSPHATASE; ESTRADIOL; OSTEOCALCIN;

ADULT; ARTICLE; BLOOD LEVEL; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FEMALE; HIP; HUMAN; HYSTERECTOMY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WRIST;

ADMINISTRATION, CUTANEOUS; ADULT; BONE DENSITY; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; HYSTERECTOMY; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; WRIST JOINT;

EID: 0036128481     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200010     Document Type: Article

References (21)

1. European consensus development conference on menopause
2. One-year open-label study of the effectiveness and tolerability of a new transdermal matrix patch for continuous estrogen replacement
3. Bioavailability study of Menorest, a new estrogen transdermal delivery system, compared with a transdermal reservoir system
4. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches
5. 17β-estradiol delivered by three different matrix patches 50 μg/day: A three way cross-over study in 21 postemenopausal women
6. Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems
7. A randomized study to compare the effectiveness, tolerability and acceptability of two different transdermal estradiol replacement therapies
8. A multicenter randomized parallel group study comparing a new estradiol matrix patch and a registered reservoir patch
9. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone
10. Accurate assessment of precision errors: How to measure the reproducibility of bone densitometry techniques
11. Matrix delivery of tansdermal 17β-estradiol for the prevention of bone loss in postmenopausal women
12. Determinants of bone loss in elderly men and women: A prospective population-based study
13. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss
14. Decrease of bone mineral density during estrogen substitution therapy
15. Non-responders to hormone replacement therapy for the prevention of postemnopausal bone loss: Do they exist?
16. A randomized, controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss
17. Bioavail-ability of estradiol from two matrix transdermal delivery systems: Menorest and Climara
18. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints
19. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women
20. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women